These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38411519)

  • 1. Association of LI-RADS and Histopathologic Features with Survival in Patients with Solitary Resected Hepatocellular Carcinoma.
    Cannella R; Matteini F; Dioguardi Burgio M; Sartoris R; Beaufrère A; Calderaro J; Mulé S; Reizine E; Luciani A; Laurent A; Seror O; Ganne-Carrié N; Wagner M; Scatton O; Vilgrain V; Cauchy F; Hobeika C; Ronot M
    Radiology; 2024 Feb; 310(2):e231160. PubMed ID: 38411519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
    van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
    Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.
    Cannella R; Dioguardi Burgio M; Beaufrère A; Trapani L; Paradis V; Hobeika C; Cauchy F; Bouattour M; Vilgrain V; Sartoris R; Ronot M
    JHEP Rep; 2021 Dec; 3(6):100380. PubMed ID: 34825155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
    Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
    Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
    Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
    AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
    [No Abstract]   [Full Text] [Related]  

  • 8. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
    Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
    Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
    Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
    Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
    Dawit H; Lam E; McInnes MDF; van der Pol CB; Bashir MR; Salameh JP; Levis B; Sirlin CB; Chernyak V; Choi SH; Kim SY; Fraum TJ; Tang A; Jiang H; Song B; Wang J; Wilson SR; Kwon H; Kierans AS; Joo I; Ronot M; Song JS; Podgórska J; Rosiak G; Kang Z; Allen BC; Costa AF
    Radiology; 2024 Feb; 310(2):e231501. PubMed ID: 38376399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
    Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
    Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percentages of Hepatocellular Carcinoma in LI-RADS Categories with CT and MRI: A Systematic Review and Meta-Analysis.
    Lee S; Kim YY; Shin J; Son WJ; Roh YH; Choi JY; Sirlin CB; Chernyak V
    Radiology; 2023 Apr; 307(1):e220646. PubMed ID: 36625748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
    Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
    Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
    Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
    Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 20. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
    Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
    Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.